Flumatinib
| CAS No. | 895519-90-1 | Cat. No. | BCP23797 |
| Name | Flumatinib | ||
| Synonyms | HHGV678; HHGV 678 ; HHGV-678; HH-GV-678; | ||
| Formula | C29H29F3N8O | M. Wt | 562.59 |
| Description | Flumatinib, also known as HHGV678 , is a selective inhibitor of BCR-ABL/PDGFR/KIT. Flumatinib is currently in Phase I and II clinical trials in China for the treatment of chronic myelogenous leukemia (CML). Flumatinib effectively overcomes drug resistance of certain KIT mutants. Flumatinib mesylate can reduce the expression of C-MYC, HIF-1 α and VEGF in U266 cell line in a time- and dose-dependent manners. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | Src/Bcr Abl PDGFR c Kit | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.